Attention Deficit Study In Healthy Children Can Proceed Under Certain Conditions, Cmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
NIH proposal to administer dextroamphetamine to healthy children represents only a slightly greater than minimal risk to study participants, FDA's Pediatric Ethics Subcommittee says. The Pediatric Advisory Committee will review the recommendations Sept. 15.
You may also be interested in...
Dextroamphetamine Study Should Avoid Prior Stimulant Use, Pediatric Cmte. Says
FDA committee accepts recommendation from its Pediatric Ethics Subcommittee to allow a study of dextroamphetamine in healthy children to proceed. Stimulants should not be provided to participants prior to enrollment, committee says.
Dextroamphetamine Study Should Avoid Prior Stimulant Use, Pediatric Cmte. Says
FDA committee accepts recommendation from its Pediatric Ethics Subcommittee to allow a study of dextroamphetamine in healthy children to proceed. Stimulants should not be provided to participants prior to enrollment, committee says.
Dextroamphetamine Study Including Healthy Children Will Be First Test For Pediatric Ethics Subcommittee
NIH study proposes single-dose administration to both children with attention deficit/hyperactivity disorder and healthy volunteers. Institutional Review Board requested special review from HHS after two divided votes.